论文部分内容阅读
目的探讨替吉奥联合同步调强放疗治疗未手术食管癌的临床疗效。方法 80例食管癌且未手术治疗的患者,随机分为研究组和对照组,各40例。对照组接受同步调强放疗治疗,研究组在对照组基础上接受替吉奥联合同步调强放疗。对比两组的治疗疗效及治疗期间毒副作用。结果研究组和对照组食管癌的治疗有效率分别为82.5%、62.5%,比较差异有统计学意义(P<0.05);研究组治疗期间出现急性放射性食管炎25例,急性放射性气管炎15例,放射性肺炎8例,骨髓抑制12例;对照组治疗期间出现急性放射性食管炎22例,急性放射性气管炎13例,放射性肺炎7例,骨髓抑制11例,两组治疗期间毒副作用结果比较差异无统计学意义(P>0.05)。结论替吉奥联合同步调强放疗治疗未手术食管癌疗效肯定,安全性高。
Objective To investigate the clinical efficacy of tegaserod combined with simultaneous intensity modulated radiotherapy in the treatment of non-surgical esophageal cancer. Methods Eighty esophageal cancer patients without esophageal cancer were randomly divided into study group and control group, 40 cases in each group. The control group received synchronous intensity modulated radiotherapy, and the study group received the combination of GIK for radiotherapy based on the control group. Compare the curative effect of the two groups and the side effects during treatment. Results The effective rates of esophageal cancer treatment in study group and control group were 82.5% and 62.5%, respectively, with significant difference (P <0.05). In the study group, 25 cases of acute esophagitis, 15 cases of acute radiation tracheitis , 8 cases of radiation pneumonitis and 12 cases of bone marrow suppression. There were 22 cases of acute radiation esophagitis, 13 cases of acute radiation bronchitis, 7 cases of radiation pneumonitis and 11 cases of bone marrow suppression during the treatment in the control group. There was no difference in the side effects between the two groups Statistical significance (P> 0.05). Conclusion TGA combined with intensity modulated radiotherapy for the treatment of esophageal cancer is effective and safe.